Esta compañía no ha anunciado ningún dividendo en el próximo trimestre, ni ha pagado dividendos en el último año.
Sobre Day One Biopharmaceuticals, Inc.
Jeremy Bender, PhD, MBA
South San FranciscoCalifornia
Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in South San Francisco, CA.
Cómo comprar acciones de Day One Biopharmaceuticals, Inc.